You are here: Industry Insights > Oral

News List

Oral Semaglutide Reduces HbA1c, Weight in Patients With T2DM drugs
August 01, 2019
Compared with placebo, oral semaglutide monotherapy is associated with superior and clinically relevant improvements in glycated hemoglobin (HbA1c) ...
Light Therapy May Prevent Oral Mucositis for Some in Cancer Tx drugs
July 23, 2019
Photobiomodulation (PBM), such as laser and other light therapies, is recommended for prevention of oral mucositis (OM) in specific populations of cancer patients...
Two pharma companies collaborate on long-acting HIV therapy europeanpharmaceuticalreview
July 12, 2019
Two pharmaceutical companies have partnered to develop a slow-release drug to treat patients with HIV.
FDA Approves Katerzia (amlodipine) Oral Suspension for Pediatric Patients 6 Years of Age and Older drugs
July 11, 2019
FDA Approves Katerzia (amlodipine) Oral Suspension for Pediatric Patients 6 Years of Age and Older.
Noramco, SPI Pharma Announce Availability of Excipient Compatibility Study for Cannabidiol Solid Oral Dosage Forms americanpharmaceuticalreview
July 10, 2019
Noramco and SPI Pharma announced they have completed work on an excipient compatibility study examining a range of options for the development of cannabidiol (CBD) solid oral dosage forms ...
Pfizer secures EC approval for oral PARP inhibitor Talzenna pharmaceutical-technology
June 26, 2019
Pfizer has secured approval from the EC for Talzenna (talazoparib) as a monotherapy to treat adult patients with germline breast cancer with gBRCA gene mutations.
Oral Steroids Increase Infection Risk in Inflammatory Disease drugs
June 25, 2019
Oral Steroids Increase Infection Risk in Inflammatory Disease.
Poor Oral Health Not Linked to Gastrointestinal Cancer Risk drugs
June 24, 2019
Poor Oral Health Not Linked to Gastrointestinal Cancer Risk.
Oral Novo Nordisk diabetes drug poses no more heart risk than placebo: study expressbpd
June 14, 2019
Patients with type 2 diabetics and either heart disease who received the drug semaglutide in pill form had a combined rate of heart attack, stroke or heart-related death of 3.8 per cent compared with 4.8 per cent for placebo
IntelGenx Appoints André Godin as President contractpharma
May 16, 2019
Will retain current role as chief financial officer.

Previous page 1 2 3 4 Next page